General Endocrinology

SUN-835 - Ethnic Disparities in Glycemic Outcomes and Antihyperglycemic Prescribing Among Adults with Newly Diagnosed Diabetes in NYC Hospital (2021-2023)

Sunday, June 14, 2026

9:00 AM - 4:00 PM CT

Location: ENDOExpo; Poster Floor

Abstract Poster Presenter(s)

Danelly Gomez D' Aza, MD

Endrocrinology, Diabetes and Metabolism fellow
Lincoln Hospital
Bronx, NY, United States

Co-Author(s)

FA

Faridat Abdulkarim, MD

Lincoln Medical and Mental Health Center/NYCHHC
Bronx, United States
TM

Tawana Mazhude, MD

Endocrinology Fellow
MONTEFIORE MEDICAL CENTER
New York, New York, United States
LR

Liya Rafeekh, MD

Internal Medicine Resident
Lincoln Medical and Mental Health Center/NYCHHC
Nyc, New York, United States
FA

Fnu Aiysha, MBBS

Resident
Lincoln Medical and Mental Health Center/NYCHHC
bronx, New York, United States
FA

Faiq Aldarabah, MD

Lincoln Medical and Mental Health Center/NYCHHC
Yonkers, New York, United States
HY

Hala Yousef, MD

LINCOLN MEDICAL & MENTAL HEALTH CTR.
Fort Lee, NJ, United States
LK

Lavina Khemani, MD

Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States
DK

Deepa Khemani, MD

Lincoln Medical and Mental Health Center/NYCHHC
Bronx, United States
HO

Han Oo, MPH

Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States
ZT

Zahra Tasneem, MD

Lincoln Hospital
bronx, United States
JV

Julia Vargas-Jerez, MD

Lincoln Hospital
bronx, United States

Senior Author/Primary Investigator(s)

Vm

Vidya menon, MD

Attending Physician
Lincoln Medical and Mental Health Center/NYCHHC
bronx, United States

Disclosure(s):

Danelly Gomez D' Aza, MD: No financial relationships to disclose

Background
New-onset diabetes during the COVID era has demonstrated variable clinical presentations; however, ethnic differences in glycemic trajectories and treatment patterns remain poorly defined. Hispanics bear a disproportionate metabolic burden. We examined longitudinal glycemic control and antihyperglycemic prescribing among Hispanic and non-Hispanic adults in the Bronx (2021–2023).
Methods
Adults with new-onset diabetes (2021–2023) were identified in a retrospective cohort at a single urban center and stratified by ethnicity (Hispanic and non-Hispanic). Electronic health records provided demographics, clinical variables, HbA1c at diagnosis and 3- and 6-month follow-up, and diabetes medication use. Longitudinal glycemic and prescribing trends were analyzed using mixed-effects models with ethnicity×time interactions, assessed by likelihood ratio testing. Analysis was conducted in R Studio.
Results
Of 458 adults, 71% were Hispanic and 29% non-Hispanic; Black race was more prevalent in non-Hispanics (78% vs 4.6%, p< 0.001). Hispanics had higher alcohol use (40% vs 26%, p=0.003), liver disease (14% vs 7.6%, p=0.053), and prior COVID infection (16% vs 6.8%, p=0.009). Non-Hispanics had higher insurance (88% vs 79%, p=0.029), prediabetes (61% vs 47%, p=0.012), and CHF (7.6% vs 2.8%, p=0.019). Hyperlipidemia rates were similar (74% vs 75%, p=0.014). Mean A1c was higher in Hispanics at diagnosis (8.9 vs 8.4, p=0.009) but similar at 3 months (7.0 vs 7.2) and 6 months (7.0 vs 7.0).
Insulin use was higher in Hispanics at baseline (17% vs 11%, p=0.20), 3 months (12.9% vs 9.1%, p=0.90), and 6 months (10.1% vs 7.6%, p=0.50) but not significant; baseline A1c predicted use (OR=2.42/unit, p< 0.001). GLP-1RA use was low at baseline and increased in both groups (4.3% vs 3.3%, p=0.3; 6 months 5.8% vs 4.5%, p=0.5); use was numerically higher in Hispanic, but ethnicity was not independently associated. DPP-4i use increased at 6 months (adj OR=5.93, p=0.023); baseline A1c predicted use (OR=2.16/unit, p< 0.001) with no ethnicity×time effect (p≥0.065). SGLT2i use rose vs baseline (3 months OR=16.0, p=0.003; 6 months OR=63.4, p< 0.001); baseline A1c predicted use (OR=1.87/unit, p=0.003); interaction estimates were unstable due to sparse events. Sulfonylurea use remained low; higher in non-Hispanics at 3 and 6 months (p≥0.6); baseline A1c predicted use (OR=1.41/unit, p=0.003). Metformin use was common throughout follow-up; ethnicity had no effect; higher A1c increased use (OR=1.61/unit, p< 0.001), while older age reduced use.
Conclusion
Prescribing patterns differed by ethnicity but were not significant. Non-Hispanic (predominantly Black) patients had lower GLP-1RA and higher sulfonylurea use despite lower insurance among Hispanics. Variation may reflect care across primary and endocrine clinics. Overall, treatment trajectories were driven by clinical rather than ethnic factors.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*